{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.15467","value":"-0.0416"},{"groupId":"OG001","spread":"0.14799","value":"-0.0152"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"150"}],"units":"Participants"}],"description":"The EQ-5D-3L is a self-administered questionnaire consisting of 5 questions, pertaining to specific health dimensions (ie, mobility, self-care, pain, usual activities, and anxiety/depression) and a health status scale. Each question has 3 levels of severity, corresponding to no problems, moderate problems and severe problems. Canadian population sample weights were used to derive health utility scores. A higher utility score represents a better health state. A clinically meaningful improvement or worsening was defined as at least 0.08 points of improvement or 0.10 points of worsening from baseline, respectively, for the EQ-5D-3L Health Utility Index. The instrument is scored using the United Kingdom (UK) index ranges from -0.594 to 1, where 0 equates to death and 1 equates to full health; -0.594 is considered 'worse than death'.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 300 mg azacitidine tablets once a day (QD) for the first 14 days of each 28-day treatment cycle until discontinuation, which includes the following reasons: disease relapse, withdrawal of consent, adverse events, participant became eligible for allogeneic bone marrow or stem cell transplantation during the treatment period, death, lost to follow-up, or protocol violation or until the end of the study.","id":"OG000","title":"Oral Azacitidine Plus Best Supportive Care"},{"description":"Participants received identically matching placebo tablets QD for the first 14 days of each 28-day treatment cycle until no longer receiving benefit, withdrawal of consent, disease relapse, adverse events, participant became eligible for allogeneic bone marrow or stem cell transplantation during the treatment period, lost to follow-up, or protocol violation or until the end of the study.","id":"OG001","title":"Placebo Plus Best Supportive Care"}],"paramType":"MEAN","populationDescription":"All treated participants with a EQ-5D-3L measurement at the end of treatment","reportingStatus":"POSTED","timeFrame":"From day 1 (randomization) up to data cut off date of 06 August 2024; approximately 135.5 months","title":"Mean Change in the European Quality of Life-Five Dimensions-Three Levels (EQ-5D-3L) Score From Baseline","type":"SECONDARY","unitOfMeasure":"Units on a scale"}